PMID- 9473601
OWN - NLM
STAT- MEDLINE
DCOM- 19980402
LR  - 20190614
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 779
IP  - 1-2
DP  - 1998 Jan 1
TI  - Facilitation of female rat lordosis behavior by hypothalamic infusion of 
      5-HT(2A/2C) receptor agonists.
PG  - 84-95
AB  - Ovariectomized rats were hormonally primed with 0.5 microg estradiol benzoate and 
      500 microg progesterone to produce two groups of rats differing in their lordosis 
      behavior. Females with a lordosis to mount (L/M) ratio < 0.5 were used to test 
      the hypothesis that 5-HT(2A/2C) receptor agonists could facilitate lordosis 
      behavior. Females with L/M ratios > or = 0.5 were used to evaluate the potential 
      suppressive effect of 5-HT(2A/2C) receptor compounds. Lordosis behavior was 
      examined following bilateral infusion of drugs into the ventromedial nucleus of 
      the hypothalamus (VMN). Drugs examined were the 5-HT(2A/2C) receptor agonist, 
      (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI), the 5-HT(2A/2C) 
      receptor antagonist, 
      3-[2-[4-(4-fluorobenzoyl)-1-piperdinyl]ethyl]-2,4(1H,3H)-quinazoli nedione 
      tartrate (ketanserin tartrate), and the non-selective 5-HT receptor agents, 
      2-(1-piperazinyl)quinoline dimaleate (quipazine) and 
      N-(3-trifluoromethylphenyl)piperazine HCl (TFMPP). Drugs with agonist action at 
      5-HT(2A/2C) receptors increased lordosis behavior in rats with low sexual 
      receptivity. The 5-HT(2A/2C) receptor antagonist, ketanserin, inhibited lordosis 
      behavior in sexually receptive rats. DOI attenuated the lordosis-inhibiting 
      effect of ketanserin, but ketanserin was less effective in preventing DOI from 
      increasing lordosis behavior. These results strengthen prior inferences that 
      activation of 5-HT(2A/2C) receptors can facilitate lordosis behavior and that the 
      VMN is one site at which such facilitation can occur.
FAU - Wolf, A
AU  - Wolf A
AD  - Department of Biology, Texas Woman's University, Denton 76204-5799, USA.
FAU - Caldarola-Pastuszka, M
AU  - Caldarola-Pastuszka M
FAU - Uphouse, L
AU  - Uphouse L
LA  - eng
GR  - R01 HD 28419/HD/NICHD NIH HHS/United States
GR  - S06 GM 08256/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Amphetamines)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 97F9DE4CT4 (Ketanserin)
RN  - OOM10GW9UE (4-iodo-2,5-dimethoxyphenylisopropylamine)
SB  - IM
MH  - Amphetamines/pharmacology
MH  - Animals
MH  - Female
MH  - Hypothalamus, Middle/*drug effects
MH  - Infusions, Parenteral
MH  - Ketanserin/*pharmacology
MH  - *Posture
MH  - Rats
MH  - Rats, Inbred F344
MH  - Serotonin Antagonists/*pharmacology
MH  - Serotonin Receptor Agonists/pharmacology
MH  - Sexual Behavior, Animal/*drug effects
EDAT- 1998/02/25 00:00
MHDA- 1998/02/25 00:01
CRDT- 1998/02/25 00:00
PHST- 1998/02/25 00:00 [pubmed]
PHST- 1998/02/25 00:01 [medline]
PHST- 1998/02/25 00:00 [entrez]
AID - S0006-8993(97)01082-2 [pii]
AID - 10.1016/s0006-8993(97)01082-2 [doi]
PST - ppublish
SO  - Brain Res. 1998 Jan 1;779(1-2):84-95. doi: 10.1016/s0006-8993(97)01082-2.